The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1–infected patients with end-stage liver disease: A prospective cohort study
- 1 September 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 15 (9) , 1133-1141
- https://doi.org/10.1002/lt.21735
Abstract
End-stage liver disease (ESLD) has become the main cause of mortality in patients coinfected by human immunodeficiency virus (HIV) and hepatitis B virus or hepatitis C virus in developed countries. The aim of this study was to describe the natural history of and prognostic factors for ESLD, with particular attention paid to features affecting liver transplantation. This was a prospective cohort study in 2 Spanish community-based hospitals performed between 1999 and 2004. One hundred four consecutive patients with cirrhosis and a first clinical decompensation of their chronic liver disease or hepatocellular carcinoma were included in the study. During a median follow-up of 10 months (endpoint: death, liver transplantation, or the last checkup date), 61 patients (59%) died. The probability of mortality (Kaplan-Meier method) at 1, 2, and 3 years was 43% [95% confidence interval (CI), 34%–60%], 59% (95% CI, 48%–70%), and 70% (95% Cl, 59%–81%), respectively. In a multivariate analysis, the Model for End-Stage Liver Disease (MELD) score and the inability to reach an undetectable plasma HIV-1 RNA viral load at any time during follow-up were the only variables independently associated with the risk of death (P < 0.001). Fifteen (14%) of the 104 patients were accepted for liver transplantation, although only 5 underwent the procedure, and 10 died while on the waiting list. The waiting list mortality rate in patients with a MELD score < 20 and in patients with a MELD score >20 was 58% and 100%, respectively (median follow-up, 5 months). In conclusion, HIV-1–infected patients with ESLD, especially those with poorly controlled HIV and a high MELD score, have a poor short-term outcome. The MELD score may be useful in deciding whether to indicate liver transplantation in these patients. However, because only a small proportion of the patients in this study were considered candidates for liver transplantation and most died while on the waiting list, few received a transplant.Keywords
This publication has 22 references indexed in Scilit:
- Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver diseaseLiver Transplantation, 2005
- Probability of liver cancer and survival in HCV‐related or alcoholic‐decompensated cirrhosis. A study of 377 patientsLiver International, 2005
- Liver Transplantation in HIV–HCV Coinfected Candidates: What Is the Most Appropriate Time for Evaluation?AIDS Research and Human Retroviruses, 2005
- HIV coinfection shortens the survival of patients with hepatitis C virus‐related decompensated cirrhosis†Hepatology, 2005
- The Survival Benefit of Liver TransplantationAmerican Journal of Transplantation, 2004
- Summary report of a national conference: Evolving concepts in liver allocation in the MELD and PELD eraLiver Transplantation, 2004
- Model for end stage liver disease score predicts mortality across a broad spectrum of liver diseaseJournal of Hepatology, 2004
- Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patientsJournal of Hepatology, 2004
- Survival of Human Immunodeficiency Virus–Infected Liver Transplant RecipientsThe Journal of Infectious Diseases, 2003
- Increasing Mortality Due to End-Stage Liver Disease in Patients with Human Immunodeficiency Virus InfectionClinical Infectious Diseases, 2001